Your browser doesn't support javascript.
loading
Finding the Role of Anifrolumab in the New Paradigm of Systemic Lupus Erythematosus Treatment.
Nieto, Romina Estefanía; Alarcón, Graciela S; Arnaud, Laurent; Pons-Estel, Guillermo Javier.
Affiliation
  • Nieto RE; R.E. Nieto, MD, Centro Regional de Enfermedades Autoinmunes y Reumáticas, Grupo Oroño, Rosario, Argentina.
  • Alarcón GS; G.S. Alarcón, MD, MPH, The University of Alabama at Birmingham, Birmingham, Alabama, USA, and Universidad Peruana Cayetano Heredia, Lima, Peru.
  • Arnaud L; L. Arnaud, MD, PhD, Department of Rheumatology, National Reference Center for Autoimmune Diseases (RESO), INSERM UMR-S 1109, Strasbourg, France.
  • Pons-Estel GJ; G.J. Pons-Estel, MD, PhD, Centro Regional de Enfermedades Autoinmunes y Reumáticas, Grupo Oroño, Rosario, Argentina.
J Rheumatol ; 2024 Oct 01.
Article in En | MEDLINE | ID: mdl-39353646
ABSTRACT
The article by Tani et al, "Anifrolumab in Refractory Systemic Lupus Erythematosus A Real-World, Multicenter Study,"1 evaluates the efficacy of anifrolumab (ANI) in patients with systemic lupus erythematosus (SLE) who failed to respond to other treatments, including biologics.There are many unmet needs in the treatment of SLE. Despite recent advances, remission and low disease activity (LDA) rates remain suboptimal; therefore, some patients with SLE are at high risk of developing endstage renal disease, organ damage, drug-related toxicities-particularly related to the prolonged use of glucocorticoids (GCs)-and premature mortality.2-4.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Rheumatol Year: 2024 Document type: Article Affiliation country: Argentina Country of publication: Canada

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Rheumatol Year: 2024 Document type: Article Affiliation country: Argentina Country of publication: Canada